Association of homocysteine and polymorphism of methylenetetrahydrofolate reductase with early-onset post stroke depression

Jingyuan Zhang, Chang Zeng, Xia Huang, Qiao Liao, Hengshu Chen, Fan Liu, Dongren Sun, Shihang Luo, Yeqing Xiao, Weiye Xu, Danfeng Zeng, Mingyu Song, Fafa TianFrontiers in Nutrition 2022 · DOI

TL;DR

Researchers have identified a clear genetic and biochemical pathway for early-onset post-stroke depression (PSD). The study demonstrates that a specific variation in the MTHFR gene (rs1801133) significantly increases PSD risk by elevating levels of homocysteine, a neurotoxic amino acid, providing a potential target for early screening and nutritional intervention.

What Problem Does This Paper Address?

Post-stroke depression (PSD) affects approximately one-third of stroke survivors, leading to poorer functional recovery, cognitive impairment, and higher mortality rates. Despite its impact, we lack reliable objective biomarkers for early identification.

While elevated levels of homocysteine (Hcy)—a sulfur-containing amino acid—are known risk factors for both stroke and general depression, the genetic architecture underlying Hcy metabolism in the context of PSD is poorly understood. This paper investigates whether polymorphisms in key Hcy-regulating genes (MTHFR, MTRR, and MTR) influence the development of "early-onset" PSD (occurring within two weeks of a stroke) and whether this effect is directly mediated by Hcy levels.

Methods

The researchers conducted a prospective cohort study of 212 acute ischemic stroke patients at Xiangya Hospital, China.

  • Clinical Assessment: PSD was diagnosed two weeks post-stroke using DSM-V criteria. Severity was measured using the Hamilton Depression Scale (HAMD-17).
  • Genotyping: The team analyzed 12 single nucleotide polymorphisms (SNPs) across three genes involved in the Hcy remethylation pathway using high-resolution melt analysis.
  • Statistical Modeling: Beyond standard logistic regression, the authors employed mediation analysis. This is a robust statistical approach used to determine if the effect of an independent variable (the gene) on a dependent variable (PSD) is "channeled" through a third intervening variable (Hcy levels).
  • Haplotype Analysis: They also performed haplotype analysis to see if specific combinations of SNPs inherited together had a stronger association with PSD than individual SNPs alone.

Datasets

The study utilized a primary clinical dataset of 212 patients recruited between July 2019 and August 2021.

  • Inclusion: Patients aged 18–75 admitted within two weeks of stroke onset.
  • Exclusion: Patients with pre-existing depression, dementia, or severe communication barriers (aphasia) were excluded to ensure the "post-stroke" nature of the depression was clearly isolated.

Key Insights and Ideas

  • The Mediation Mechanism: The most significant "aha moment" is the confirmation of a biological pathway. The MTHFR rs1801133 AA genotype doesn't just correlate with PSD; it appears to drive PSD by increasing Hcy levels. When the effect of Hcy was statistically removed, the direct link between the gene and PSD vanished, suggesting Hcy is the primary effector.
  • Neurotoxic Pathway: The authors suggest Hcy contributes to PSD through several mechanisms: reducing levels of monoamine neurotransmitters (dopamine, norepinephrine, serotonin), causing DNA damage in the central nervous system, and triggering inflammatory processes.
  • Genetic Specificity: While 12 SNPs were tested across three genes, only the MTHFR variants showed strong associations. This highlights MTHFR as the critical genetic bottleneck in the Hcy-PSD relationship.

Key Results

  • Incidence: 38.2% of the cohort (81 patients) developed early-onset PSD.
  • Hcy Levels: Patients with PSD had significantly higher Hcy levels (17.06 ± 8.35 μmol/L) compared to those without (14.63 ± 6.57 μmol/L, p = 0.019).
  • Genetic Risk: The AA genotype of rs1801133 was associated with a 4.021-fold increased risk of PSD after adjusting for confounding factors like age, gender, and stroke severity (95% CI: 1.459–11.080, p = 0.007).
  • Haplotype Risk: The "GTAG" haplotype (a specific combination of four MTHFR SNPs) was associated with an 85% increased risk of PSD (OR = 1.852).

Limitations and Future Work

The authors acknowledge several constraints:

  • Sample Size: The study was conducted at a single clinical institution with a relatively small sample size (n=212), which may limit the generalizability of the findings.
  • Snapshot Measurement: Hcy was only measured at admission. Because Hcy levels can fluctuate, longitudinal tracking throughout the recovery process would provide a clearer picture.
  • Nutritional Variables: The study did not account for the patients' history of B-vitamin or folic acid supplementation, which are known to lower Hcy levels and could influence the results.
  • Scope: The study focused only on early-onset PSD. Future research is needed to determine if these same genetic markers predict late-onset depression (months or years after a stroke).

Overall, the paper suggests that clinicians should pay closer attention to Hcy levels in stroke patients, as Hcy-lowering treatments (like folic acid) might represent a low-cost, low-risk preventative strategy for PSD.

Summary updated

Abstract

MTHFR rs1801133 and Hcy were associated with PSD, and MTHFR rs1801133 may exert an effect on PSD <i>via</i> mediating Hcy level. This offers a new perspective for treating PSD and understanding the mechanism of PSD.
BibTeX
@inproceedings{zhang2022association,
  author = {Jingyuan Zhang and Chang Zeng and Xia Huang and Qiao Liao and Hengshu Chen and Fan Liu and Dongren Sun and Shihang Luo and Yeqing Xiao and Weiye Xu and Danfeng Zeng and Mingyu Song and Fafa Tian},
  title = {{Association of homocysteine and polymorphism of methylenetetrahydrofolate reductase with early-onset post stroke depression}},
  booktitle = {Frontiers in Nutrition},
  year = {2022},
  doi = {10.3389/fnut.2022.1078281},
}
Figure